SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Meta Expands AI Training With Employee Activity Tracking Tools 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
REHOVOT, Israel, March 02, 2016 -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences:
- Cowen and Company 36th Annual Health Care Conference taking place in Boston, Massachusetts from March 7 – 9, 2016. Dr. Lieberman’s presentation will take place on Wednesday, March 9, at 11:20am ET.
- 28th Annual ROTH Conference taking place in Dana Point, California from March 13 – 16, 2016. Dr. Lieberman’s presentation will take place on Monday, March 14 at 9:30am PT, 12:30pm ET.
To access the live webcast of the presentations, please visit ir.neuroderm.com/. A replay will be available following the presentation.
About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Rabin Science Park, Rehovot, Israel.
NeuroDerm Contact:
Oded S. Lieberman, PhD MBA, CEO
[email protected]
Tel.: +972-8-946 2729
Cell: +1-617-517 6077
U.S. Investor Contact:
David Carey
Lazar Partners Ltd.
[email protected]
+212-867-1762
